



**Media Release**

## ORIL Receives Funding Boost

**Perth, February 3, 2014:** Oncology Research International Limited (ORIL) today announced a further \$1.4M investment by Gina Rinehart's private company, Hanrine Investments Pty Ltd, has been approved by ORIL shareholders at a recent General Meeting in Perth.

Hanrine is a wholly owned subsidiary of Hancock Prospecting Pty Ltd. This latest investment by Hanrine takes its total investment in ORIL to 27.23%, and provides the necessary financial support for the company to complete its preclinical and clinical program to Phase 1, scheduled for completion by 2015.

In difficult times for biotech, ORIL has raised \$9.2M through equity investment over the past three (3) years to fund its novel oncology program.

Dr Philip Marshall, the company's CEO, said this is a remarkable achievement given the tight economic conditions.

"We are delighted with Hanrine's increased investment, which represents a significant endorsement of ORIL's technology platform and future."

-ENDS-

**For further information contact:**

### **Media**

Amanda Loh

Tel: +61 3 8866 1210

Email: [aloh@buchanwe.com.au](mailto:aloh@buchanwe.com.au)

### **About ORIL and its technology**

ORIL is an Australian, public, unlisted company which has identified and developed a family of plant-based compounds with a novel mode of action that targets the cancer cell membrane.

This innovative mode of action causes cancer cells to undergo apoptosis - a natural process resulting in cell death - inducing cancer cells to self-destruct without affecting normal healthy cells. This "first in class" mode of action works across a wide range of cancer types and is currently not matched by available cancer drugs. ORIL believes this technology provides a distinct advantage over conventional and/or targeted anticancer agents that invariably cause adverse side effects and lose their effectiveness after a relatively short period of time as the cancer develops drug resistance.

**About ORIL 007**

ORIL007 is the company's lead oncology compound originally isolated from a range of commonly found plants, albeit in trace amounts. ORIL has designed a novel synthetic route and manufactured commercial quantities of ORIL007 under Good Manufacturing Practices for its program. The species of these plants and the method of synthesis are commercial in confidence to the company's intellectual property. ORIL007 is currently in late preclinical testing with plans to complete Phase I trial testing for drug safety, tolerability and indicative clinical efficacy in multiple cancer types by 2015.